
FDA Approves New Influenza Vaccine Manufactured with Novel Technology
FDA has approved Protein Sciences's FluBlok, a seasonal influenza vaccine made with novel technology. FluBlok uses recombinant DNA and a modified baculovirus (a virus that infects insects) to produce a safe and effective human flu vaccine. FDA approved FluBlok for people 18–49 years old.
FDA has approved Protein Sciences’s FluBlok, a seasonal influenza vaccine made with novel technology. FluBlok uses recombinant DNA and a modified baculovirus (a virus that infects insects) to produce a safe and effective human influenza vaccine. FDA approved FluBlok for people 18–49 years old.
“This approval represents a technological advance in the manufacturing of an influenza vaccine,” said Karen Midthun, director of FDA’s Center for Biologics Evaluation and Research, in a Jan. 16, 2013,
According to a
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.